Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: Determination of incidence, distribution patterns, and report of a novel KIT mutation

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 865-876

  Ahmad, Firoz ^a   D'Souza, Wilma ^a   Mandava, Swarna ^a   Ranjan Das, Bibhu ^a  

^a Super Religare Laboratories Ltd   (India)

Author keywords

AML; cytogenetics; India; WT1 and KIT gene mutation

Indexed keywords

CD135 ANTIGEN; HEMOGLOBIN; NUCLEOPHOSMIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CORRELATION ANALYSIS; CYTOGENETICS; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INCIDENCE; INDIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; NUCLEIC ACID BASE SUBSTITUTION; POPULATION DISTRIBUTION; PRIORITY JOURNAL; SCHOOL CHILD; SEX; THROMBOCYTE COUNT;

DNA MUTATIONAL ANALYSIS; EXONS; FMS-LIKE TYROSINE KINASE 3; HUMANS; INCIDENCE; INDIA; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; WT1 PROTEINS;

EID: 79955061900     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.552137     Document Type: Article

References (54)

1. Cheson BD, Bennett JM, Kopecky KJ, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;15:4642-4649. (Pubitemid 46594039)
2. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336. (Pubitemid 35429670)
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 1998;92: 2322-2333. (Pubitemid 28452973)
4. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev 2004;18:115-136. (Pubitemid 38380667)
5. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907. (Pubitemid 44794525)
6. Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:82-101.
7. Mrozek K, Dohner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 2007;14:106-114. (Pubitemid 46175094)
8. Gaidzik V, Dohner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008;35:346-355.
9. Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007;21:550-551.
10. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008;26:4595-4602.
11. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia working party. J Clin Oncol 2008;26:5429-5435.
12. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009;115:3719-3727.
13. Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009;113:4505-4511.
14. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010;115:5222-5231.
15. Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2010;116:702-710.
16. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991;11:1707-1712. (Pubitemid 21895530)
17. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320. (Pubitemid 27236656)
18. Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20:1897-1909. (Pubitemid 32397392)
19. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6: 405-409.
20. King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996 15;87:2171-2179.
21. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21: 868-876. (Pubitemid 46672061)
22. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17. (Pubitemid 46965072)
23. Abbas S, Erpelinck C, Goudswaard C, Lowenberg B, Valk P. Mutant Wilms' Tumor 1 (WT1) mRNA with premature termination codons is sensitive to nonsense-mediated RNA decay in acute myeloid leukemia (AML). Blood 2008;112 (Suppl. 1): Abstract 2538.
24. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91:2961-2968. (Pubitemid 28227547)
25. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997;9:209-225. (Pubitemid 27138814)
26. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010;28:13-19.
27. Kahler C, Didlaukat S, Feller AC, Merz H. Sensitive and reliable detection of KIT point mutation Asp 816 to Val in pathological material. Diagn Pathol 2007;2:37-41.
28. Liu H, Chen X, Focia PJ, He X. Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases. EMBO J 2007;26:891-901.
29. Zaker F, Mohammadzadeh M, Mohammadi M. Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes. Arch Iran Med 2010;13:21-25.
30. Beghini AP, Peterlongo CB, Ripamonti L, Larizza R, Cairoli E. C-KIT mutation in core binding factor leukemias. Blood 2000;95:726-727.
31. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004;104: 1931-1939. (Pubitemid 39297841)
32. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-576. (Pubitemid 32506764)
33. Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer 1999;25:176-183. (Pubitemid 29226601)
34. Hou H, Huang TC, Lin L, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system Blood 2010;115:5222-5231.
35. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/ overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005;102:1104-1109. (Pubitemid 40170733)
36. Sritana N, Auewarakul CU. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. Exp Mol Pathol 2008;85: 227-231.
37. Shimada A, Tomohiko T, Ken T, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006;107:1806-1809. (Pubitemid 43289357)
38. Ahmad F, Mandava S, Das BR. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest 2010;28:63-73.
39. Ahmad F, Mandava S, Das BR. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol 2009;27:90-97.
40. Shaffer LG, Tommerup N, editors. ISCN 2005: an international system for human cytogenetic nomenclature (2005). Basel: S. Karger; 2005.
41. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-KIT, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006;20:965-970. (Pubitemid 43797286)
42. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005;19:1536-1542. (Pubitemid 43090396)
43. Schnittger S, Kohl TM, Haferlach T, et al. KITD816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107: 1791-1799. (Pubitemid 43289355)
44. Lasa A, Carricondo MT, Carnicer MJ, Perea G, Aventin A, Nomdedeu JF. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica 2006;91: 1283-1284. (Pubitemid 44408448)
45. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004;89:920-925. (Pubitemid 39049899)
46. Thiede C, Illmer T, Soucek S, Schaich M, Ehninger G. Mutations in the WT1 transcription factor are associated with inferior overall survival - an analysis in 368 AML patients with normal karyotype under 60 years treated in the AML96 protocol of the DSIL. Haematologica 2008;93(Suppl. 1): Abstract 0156.
47. Spinelli O, Tosi M, Guerini V, et al. Prognostic significance of molecular markers in normal karyotype-AML: a single centre experience. Haematologica 2008;93(Suppl. 1): Abstract 0509.
48. Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009;113:5951-5960.
49. Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010;28:578-585.
50. Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:788-792.
51. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010;115:2372-2379.
52. Lapillonne H, Llopis L, Auvrignon A, et al. Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. Leukemia 2010;24:205-209.
53. Little M, Holmes G, Bickmore W, et al. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995;4: 351-358.
54. Gari M, Goodeve A, Wilson G, et al. c-KIT protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900. (Pubitemid 29309094)